AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Atopic dermatitis in a phenylketonuric untreated patient

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/156436> since

Published version:

DOI:10.1111/ijd.12043

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Fava p, Fierro MT, Brizio M, Marra E, Spada M, Bernengo MG
Atopic dermatitis in a phenylketonuric untreated patient
INTERNATIONAL JOURNAL OF DERMATOLOGY (2013) [Epub ahead
of print]
DOI: 10.1111/ijd.12043

Atopic dermatitis in a phenylketonuric untreated patient

Paolo Fava¹, MD, Maria Teresa Fierro¹, MD, Matteo Brizio¹, MD, Elena Marra¹, MD, Marco Spada², MD, and Maria Grazia Bernengo¹, MD

¹ Department of Biomedical Sciences and Human Oncology, Section of Dermatology, University of Turin, Turin, Italy,

² Department of Pediatric and Adolescence Sciences, University of Turin, Turin, Italy

Correspondence

Maria Teresa Fierro, MD Department of Medical Sciences Section of Dermatology, University of Turin v. Cherasco 23, 10126, Torino, Italy E-mail: mariateresa.fierro@unito.it

Conflicts of interest: None.

doi: 10.1111/ijd.12043

Phenylketonuria (PKU) is an autosomal recessive metabolic disease, which is seen in approximately 1:12,000–1:18,000 newborn.^{1,2} PKU results from a deficiency of phenylalanine hydroxylase, the enzyme converting phenylalanine into tyrosine. Hyperphenylalaninemia is the biochemical hallmark of PKU. Classic phenylketonuria is caused by a complete or near-complete deficiency of phenylalanine hydroxylase activity;³ without dietary restriction of phenylalanine, patients will develop profound and irreversible intellectual disability and neurological disturbances.² The natural history of this disorder has been changed since newborn screening was introduced in the late 1960s, and affected children are now maintained on a phenylalanine restricted diet, which must commence as soon as possible after birth and should continue for life.^{4,5} Skin disorders linked with PKU are principally scleroderma-like changes with guttate or generalized morphea and hypopigmentation; dermatitis is also described in these patients.^{6–10} An accurate description of clinical features of this dermatitis cannot be found in the literature, and the relationship with atopic dermatitis, a multifactorial, inflammatory skin disease with a chronic or relapsing course, has never been analyzed thoroughly.^{11–13}

Case report

We report the case of a 44-year-old Caucasian man with PKU complicated with atopic dermatitis referred to our institution for the worsening of erythematous areas of white scales, crusts, and multiple scratching lesions located at forearms, shoulders, inferior limbs, and sacral region (Figs. 1a and 2a). The Fitzpatrick phototype was I. Personal history revealed PKU first diagnosed at eight years old; PKU was not recognized in the neonatal period, thus the patient had a free diet that resulted in a permanent mental handicap. In addition, after PKU diagnosis, adherence to dietary restriction was poor because of low family compliance. Since childhood, the patient has suffered from dermatitis with chronic pruritus and frequent infectious episodes, which has been diagnosed as atopic dermatitis and treated for years with topical steroids. Previous patch tests (with the European Standard Series of haptens) were negative. Biochemistry revealed leukocytosis (white blood cell count $10.34 \times 10^9/L$) with eosinophilia (13%; absolute count: $1.87 \times 10^9/L$) and elevation of IgE levels (4145 kUI/L); plasma phenylalanine concentration was 1250 $\mu\text{mol/L}$ (normal values lower than 120 $\mu\text{mol/L}$); flow cytometry on peripheral blood lymphocytes failed to document an imbalance between different T-cell populations. Skin culture on lesions identified a non-MRSA *Staphylococcus aureus*. Histological findings were nonspecific, showing spongiosis, acanthosis,

hyperkeratosis, and increased number of dermal lymphocytes (Fig. 3). The patient was treated with IV steroids (IV methylprednisolone 0.5 mg/kg daily), azithromycin, and topical tacrolimus. A strict, low phenylalanine diet was started with a phenylalanine intake not exceeding 400 mg/day. IV steroid was tapered, and the patient was discharged with topical tacrolimus and dietary treatment only. Owing to good compliance with the diet, the plasma phenylalanine concentration dropped to 450 μ mol/L in one month; tacrolimus was stopped one month later. After six months of dietary treatment, we observed an almost complete cutaneous response with regression of erythematous lesions and itching (Figs. 1b and 2b), together with a reduction of IgE (2712 kU/L) and eosinophil value (0.7 $\times 10^9$ /L). This case could be considered as a PKU-related eczema but also a true extrinsic atopic dermatitis. Its peculiarity is represented by the surprising long-lasting clinical response to the dietary regimen. The report by Riva et al. demonstrates that IgE levels are higher in patients with PKU than in the normal population and suggests that a dietary regimen can control the development of immunoallergic signs and symptoms.¹¹

Our report confirms that dietary regimen could not only avoid mental retardation in childhood but also reduce the incidence of cutaneous manifestations in PKU. This evidence can also provide an explanation to the reduced incidence of eczema in the patient with PKU observed in the last years.

References

- 1 Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. *Br Med J* 1991; 303: 333–335.
- 2 Walter JH. Late effects of phenylketonuria. *Arch Dis Childh* 1995; 73: 485–486.
- 3 Scriver CR, Clow CR. Phenylketonuria: epitome of human biochemical genetics. *N Engl J Med* 1980; 303: 1336–1342.
- 4 Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. *Clin Biochem Rev* 2008; 29: 31–41.
- 5 Longo N, Ernst S. Management of phenylketonuria. *US Pediatr* 2008; 4: 59–62.
- 6 Foti R, Leonardi R, Rondinone R, et al. Scleroderma-like disorders. *Autoimmunity Rev* 2008; 7: 331–339.
- 7 Guillet G, Dore N, Hehunstre J, et al. Pseudoscleroderma and phenylketonuria. *Int J Dermatol* 1983; 22: 422–426.
- 8 Al-Mayouf SM, Al-Owain MA. Progressive sclerodermatous skin changes in a child with phenylketonuria. *Pediatr Dermatol* 2006; 23: 136–138.
- 9 Fistarol SK, Itin PH. Disorders of pigmentation. *J Dtsch Dermatol Ges* 2010; 8: 187–201.
- 10 Belloso LM, Lowitt MH. Cutaneous findings in a 51- year-old man with phenylketonuria. *J Am Acad Dermatol* 2003; 49: S190–S192.
- 11 Riva E, Fiocchi A, Agostoni C, et al. PKU-related dysgammaglobulinaemia: the effect of diet therapy on IgE and allergic sensitization. *J Inherit Metab Dis* 1994; 17: 710–717.
- 12 De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune defects? *J Invest Dermatol* 2009; 129: 14–30.
- 13 Fisch RO, Tsai MY, Gentry WC Jr. Studies of phenylketonurics with dermatitis. *J Am Acad Dermatol* 1981; 4: 284–290.

Figure 1 Clinical picture of the patient before (a) and 6 months after (b) phenylalanine-restricted diet

Figure 2 Clinical picture of the patient before (a) and 6 months after (b) phenylalanine-restricted diet

Figure 3 Skin biopsy shows spongiosis, acanthosis, hyperkeratosis, and increased number of dermal lymphocytes (hematoxylin and eosin, 9100)